Aging immune cells may block cancer treatments

Senescent CD8 T effector memory cells lose their ability to fight disease and respond to immunotherapy.

Senescent CD8 T effector memory (EM) cells are functionally impaired. These cells increase in aging and disease. They also act as a barrier to immunotherapy.

Researchers used single-cell RNA sequencing to study human SA-βGal-expressing (SA-βGal high) CD8 T effector memory (EM) cells. They found these cells develop at all stages of T cell differentiation. These cells increase in abundance with human aging.

SA-βGal high CD8 T EM cells express classical markers of senescence. These cells have a significantly impaired ability to proliferate, produce cytokines, and eliminate senescent human stromal cells. Senescence is distinct from and dominant over T cell exhaustion.

The gene signatures of these cells are enriched in older human donors. They are also found in patients with cancer, smokers, and those with age-related disorders. This senescence limits the response of CD8 T EM cells to immune checkpoint blockade.

Senescent cells play roles in biological processes that promote fitness and health. However, their timely elimination by immune cells is critical to maintain tissue homeostasis and prevent disease.

Key facts

  • Senescent CD8 T EM cells are enriched in aging, cancer, and smokers.
  • T cell senescence is distinct from and dominant over T cell exhaustion.
  • Senescence limits the response of CD8 T EM cells to immune checkpoint blockade.

All sections

Edition